tiprankstipranks
Trending News
More News >
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
US Market
Advertisement

Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

Compare
333 Followers
See the Price Targets and Ratings of:

DNTH Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Dianthus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DNTH Stock 12 Month Forecast

Average Price Target

$47.40
▲(138.91%Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is $47.40 with a high forecast of $52.00 and a low forecast of $40.00. The average price target represents a 138.91% change from the last price of $19.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","53":"$53","25.25":"$25.3","34.5":"$34.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25.25,34.5,43.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.96,20.57846153846154,23.196923076923078,25.815384615384616,28.433846153846154,31.052307692307693,33.67076923076923,36.28923076923077,38.90769230769231,41.526153846153846,44.144615384615385,46.76307692307692,49.38153846153846,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.96,20.224615384615387,22.48923076923077,24.753846153846155,27.018461538461537,29.283076923076923,31.54769230769231,33.81230769230769,36.07692307692308,38.34153846153846,40.606153846153845,42.87076923076923,45.135384615384616,{"y":47.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.96,19.655384615384616,21.35076923076923,23.046153846153846,24.74153846153846,26.43692307692308,28.13230769230769,29.82769230769231,31.52307692307692,33.21846153846154,34.91384615384615,36.60923076923077,38.30461538461539,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.53,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.61,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$52.00Average Price Target$47.40Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on DNTH
TipRanks AITipRanks
Not Ranked
TipRanks
$21
Hold
5.85%
Upside
Reiterated
07/10/25
Dianthus Therapeutics shows strong technical momentum, but financial performance is hampered by ongoing losses and negative cash flow. Valuation is concerning with a negative P/E ratio. The absence of recent earnings call insights limits further assessment.
William Blair Analyst forecast on DNTH
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
07/14/25
Dianthus Therapeutics' DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts
Stifel Nicolaus Analyst forecast on DNTH
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$52
Buy
162.10%
Upside
Reiterated
07/14/25
Dianthus Therapeutics (DNTH) Gets a Buy from Stifel Nicolaus
Evercore ISI
$50
Buy
152.02%
Upside
Reiterated
07/11/25
Evercore ISI Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
LifeSci Capital Analyst forecast on DNTH
Rami KatkhudaLifeSci Capital
LifeSci Capital
$45
Buy
126.81%
Upside
Reiterated
06/30/25
Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
Robert W. Baird Analyst forecast on DNTH
Joel BeattyRobert W. Baird
Robert W. Baird
$58$50
Buy
152.02%
Upside
Reiterated
05/13/25
Dianthus price target lowered to $50 from $58 at BairdDianthus price target lowered to $50 from $58 at Baird
TD Cowen Analyst forecast on DNTH
Yaron WerberTD Cowen
TD Cowen
Buy
Reiterated
05/12/25
Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
H.C. Wainwright Analyst forecast on DNTH
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$40
Buy
101.61%
Upside
Reiterated
05/12/25
Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
Wedbush Analyst forecast on DNTH
Unknown AnalystWedbush
Not Ranked
Wedbush
$36
Buy
81.45%
Upside
Reiterated
03/12/25
Citi
$40
Buy
101.61%
Upside
Reiterated
03/11/25
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress
Oppenheimer Analyst forecast on DNTH
Trevor AllredOppenheimer
Oppenheimer
$52
Buy
162.10%
Upside
Assigned
11/11/24
Dianthus price target raised to $52 from $48 at OppenheimerDianthus price target raised to $52 from $48 at Oppenheimer
Guggenheim Analyst forecast on DNTH
Yatin SunejaGuggenheim
Guggenheim
Buy
Reiterated
10/04/24
Guggenheim reiterates Buy Rating on Dianthus Therapeutics (DNTH)Guggenheim analyst Yatin Suneja reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on DNTH
TipRanks AITipRanks
Not Ranked
TipRanks
$21
Hold
5.85%
Upside
Reiterated
07/10/25
Dianthus Therapeutics shows strong technical momentum, but financial performance is hampered by ongoing losses and negative cash flow. Valuation is concerning with a negative P/E ratio. The absence of recent earnings call insights limits further assessment.
William Blair Analyst forecast on DNTH
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
07/14/25
Dianthus Therapeutics' DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts
Stifel Nicolaus Analyst forecast on DNTH
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$52
Buy
162.10%
Upside
Reiterated
07/14/25
Dianthus Therapeutics (DNTH) Gets a Buy from Stifel Nicolaus
Evercore ISI
$50
Buy
152.02%
Upside
Reiterated
07/11/25
Evercore ISI Sticks to Their Buy Rating for Dianthus Therapeutics (DNTH)
LifeSci Capital Analyst forecast on DNTH
Rami KatkhudaLifeSci Capital
LifeSci Capital
$45
Buy
126.81%
Upside
Reiterated
06/30/25
Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
Robert W. Baird Analyst forecast on DNTH
Joel BeattyRobert W. Baird
Robert W. Baird
$58$50
Buy
152.02%
Upside
Reiterated
05/13/25
Dianthus price target lowered to $50 from $58 at BairdDianthus price target lowered to $50 from $58 at Baird
TD Cowen Analyst forecast on DNTH
Yaron WerberTD Cowen
TD Cowen
Buy
Reiterated
05/12/25
Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
H.C. Wainwright Analyst forecast on DNTH
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$40
Buy
101.61%
Upside
Reiterated
05/12/25
Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
Wedbush Analyst forecast on DNTH
Unknown AnalystWedbush
Not Ranked
Wedbush
$36
Buy
81.45%
Upside
Reiterated
03/12/25
Citi
$40
Buy
101.61%
Upside
Reiterated
03/11/25
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress
Oppenheimer Analyst forecast on DNTH
Trevor AllredOppenheimer
Oppenheimer
$52
Buy
162.10%
Upside
Assigned
11/11/24
Dianthus price target raised to $52 from $48 at OppenheimerDianthus price target raised to $52 from $48 at Oppenheimer
Guggenheim Analyst forecast on DNTH
Yatin SunejaGuggenheim
Guggenheim
Buy
Reiterated
10/04/24
Guggenheim reiterates Buy Rating on Dianthus Therapeutics (DNTH)Guggenheim analyst Yatin Suneja reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

1 Month
xxx
Success Rate
3/7 ratings generated profit
43%
Average Return
-5.06%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of -5.06% per trade.
3 Months
xxx
Success Rate
2/5 ratings generated profit
40%
Average Return
-1.88%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -1.88% per trade.
1 Year
Alex Thompson CFAStifel Nicolaus
Success Rate
2/7 ratings generated profit
29%
Average Return
-9.09%
reiterated a buy rating 4 days ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -9.09% per trade.
2 Years
xxx
Success Rate
1/5 ratings generated profit
20%
Average Return
-21.10%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -21.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNTH Analyst Recommendation Trends

Rating
Feb 25
Mar 25
May 25
Jun 25
Jul 25
Strong Buy
6
8
11
14
12
Buy
3
3
3
2
2
Hold
0
0
0
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
11
14
18
16
In the current month, DNTH has received 14 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DNTH average Analyst price target in the past 3 months is 47.40.
Each month's total comprises the sum of three months' worth of ratings.

DNTH Financial Forecast

No data currently available

DNTH Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

DNTH Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

DNTH Stock Forecast FAQ

What is DNTH’s average 12-month price target, according to analysts?
Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is 47.40.
    What is DNTH’s upside potential, based on the analysts’ average price target?
    Dianthus Therapeutics has 138.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DNTH a Buy, Sell or Hold?
          Dianthus Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Dianthus Therapeutics’s price target?
            The average price target for Dianthus Therapeutics is 47.40. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $52.00 ,the lowest forecast is $40.00. The average price target represents 138.91% Increase from the current price of $19.84.
              What do analysts say about Dianthus Therapeutics?
              Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of DNTH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis